{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:56:04Z","timestamp":1793476564690,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Domp\u00e8 farmaceutici s.p.a"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11739-023-03309-5","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T10:01:58Z","timestamp":1685440918000},"page":"1647-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Therapeutic inhibition of CXCR1\/2: where do we stand?"],"prefix":"10.1007","volume":"18","author":[{"given":"Sebastian","family":"Sitaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Budke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7689-3613","authenticated-orcid":false,"given":"Markus","family":"Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"3309_CR1","doi-asserted-by":"publisher","first-page":"108257","DOI":"10.1016\/j.pharmthera.2022.108257","volume":"237","author":"K Dhayni","year":"2022","unstructured":"Dhayni K, Zibara K, Issa H et al (2022) Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases. Pharmacol Ther 237:108257. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108257","journal-title":"Pharmacol Ther"},{"key":"3309_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00471","author":"PHC Leliefeld","year":"2015","unstructured":"Leliefeld PHC, Koenderman L, Pillay J (2015) How neutrophils shape adaptive immune responses. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00471","journal-title":"Front Immunol"},{"key":"3309_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519. https:\/\/doi.org\/10.1038\/nri3024","journal-title":"Nat Rev Immunol"},{"key":"3309_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/carcin\/bgs123","volume":"33","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949\u2013955. https:\/\/doi.org\/10.1093\/carcin\/bgs123","journal-title":"Carcinogenesis"},{"key":"3309_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molimm.2012.11.006","volume":"55","author":"S Schmidt","year":"2013","unstructured":"Schmidt S, Moser M, Sperandio M (2013) The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 55:49\u201358. https:\/\/doi.org\/10.1016\/j.molimm.2012.11.006","journal-title":"Mol Immunol"},{"key":"3309_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","volume":"19","author":"T N\u00e9meth","year":"2020","unstructured":"N\u00e9meth T, Sperandio M, M\u00f3csai A (2020) Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov 19:253\u2013275. https:\/\/doi.org\/10.1038\/s41573-019-0054-z","journal-title":"Nat Rev Drug Discov"},{"key":"3309_CR7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3324\/haematol.2019.225722","volume":"105","author":"I Rohwedder","year":"2020","unstructured":"Rohwedder I, Kurz ARM, Pruenster M et al (2020) Src family kinase-mediated vesicle trafficking is critical for neutrophil basement membrane penetration. Haematologica 105:1845\u20131856. https:\/\/doi.org\/10.3324\/haematol.2019.225722","journal-title":"Haematologica"},{"key":"3309_CR8","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/ijms23042168","volume":"23","author":"J Korbecki","year":"2022","unstructured":"Korbecki J, Kupnicka P, Chlubek M et al (2022) CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer. Int J Mol Sci 23:2168. https:\/\/doi.org\/10.3390\/ijms23042168","journal-title":"Int J Mol Sci"},{"key":"3309_CR9","first-page":"145","volume":"52","author":"PM Murphy","year":"2000","unstructured":"Murphy PM, Baggiolini M, Charo IF et al (2000) International union of pharmacology. XXII. Nomenclat Chemokine Recept Pharmacol Rev 52:145\u2013176","journal-title":"Nomenclat Chemokine Recept Pharmacol Rev"},{"key":"3309_CR10","doi-asserted-by":"publisher","first-page":"29355","DOI":"10.1016\/S0021-9258(18)43882-3","volume":"269","author":"CR Bozic","year":"1994","unstructured":"Bozic CR, Gerard NP, von Uexkull-Guldenband C et al (1994) The murine interleukin 8 type B receptor homologue and its ligands. expression and biological characterization. J Biol Chem 269:29355\u201329358","journal-title":"J Biol Chem"},{"key":"3309_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nature11580","volume":"491","author":"SH Park","year":"2012","unstructured":"Park SH, Das BB, Casagrande F et al (2012) Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491:779\u2013783. https:\/\/doi.org\/10.1038\/nature11580","journal-title":"Nature"},{"key":"3309_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbrc.2017.02.010","volume":"485","author":"N Spellmon","year":"2017","unstructured":"Spellmon N, Holcomb J, Niu A et al (2017) Structural basis of PDZ-mediated chemokine receptor CXCR2 scaffolding by guanine nucleotide exchange factor PDZ-RhoGEF. Biochem Biophys Res Commun 485:529\u2013534. https:\/\/doi.org\/10.1016\/j.bbrc.2017.02.010","journal-title":"Biochem Biophys Res Commun"},{"key":"3309_CR13","doi-asserted-by":"publisher","first-page":"e94178","DOI":"10.1371\/journal.pone.0094178","volume":"9","author":"J-W Liou","year":"2014","unstructured":"Liou J-W, Chang F-T, Chung Y et al (2014) In silico analysis reveals sequential interactions and protein conformational changes during the binding of chemokine CXCL-8 to its receptor CXCR1. PLoS ONE 9:e94178. https:\/\/doi.org\/10.1371\/journal.pone.0094178","journal-title":"PLoS ONE"},{"key":"3309_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI114265","volume":"84","author":"M Baggiolini","year":"1989","unstructured":"Baggiolini M, Walz A, Kunkel SL (1989) Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045\u20131049","journal-title":"J Clin Invest"},{"key":"3309_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023913","author":"A Mortier","year":"2011","unstructured":"Mortier A, Berghmans N, Ronsse I et al (2011) Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0023913","journal-title":"PLoS ONE"},{"key":"3309_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/bi00459a004","volume":"29","author":"GM Clore","year":"1990","unstructured":"Clore GM, Appella E, Yamada M et al (1990) Three-dimensional structure of interleukin 8 in solution. Biochemistry 29:1689\u20131696","journal-title":"Biochemistry"},{"key":"3309_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.4049\/jimmunol.155.3.1428","volume":"155","author":"ME Hammond","year":"1995","unstructured":"Hammond ME, Lapointe GR, Feucht PH et al (1995) IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 155:1428\u20131433","journal-title":"J Immunol"},{"key":"3309_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nri3399","volume":"13","author":"E Kolaczkowska","year":"2013","unstructured":"Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159\u2013175. https:\/\/doi.org\/10.1038\/nri3399","journal-title":"Nat Rev Immunol"},{"key":"3309_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/07357909309046949","volume":"11","author":"CA H\u00e9bert","year":"1993","unstructured":"H\u00e9bert CA, Baker JB (1993) Interleukin-8: a review. Cancer Invest 11:743\u2013750. https:\/\/doi.org\/10.3109\/07357909309046949","journal-title":"Cancer Invest"},{"key":"3309_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0167-5699(94)90314-X","volume":"15","author":"R Horuk","year":"1994","unstructured":"Horuk R (1994) The interleukin-8-receptor family: from chemokines to malaria. Immunol Today 15:169\u2013174. https:\/\/doi.org\/10.1016\/0167-5699(94)90314-X","journal-title":"Immunol Today"},{"key":"3309_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nm1567","volume":"13","author":"J Bernhagen","year":"2007","unstructured":"Bernhagen J, Krohn R, Lue H et al (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13:587\u2013596. https:\/\/doi.org\/10.1038\/nm1567","journal-title":"Nat Med"},{"key":"3309_CR22","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.4049\/jimmunol.0900305","volume":"183","author":"MW Nasser","year":"1950","unstructured":"Nasser MW, Raghuwanshi SK, Grant DJ et al (1950) (2009) Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol Baltim Md 183:3425\u20133432. https:\/\/doi.org\/10.4049\/jimmunol.0900305","journal-title":"J Immunol Baltim Md"},{"key":"3309_CR23","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.4049\/jimmunol.151.11.6347","volume":"151","author":"K Ley","year":"1993","unstructured":"Ley K, Baker JB, Cybulsky MI et al (1993) Intravenous interleukin-8 inhibits granulocyte emigration from rabbit mesenteric venules without altering L-selectin expression or leukocyte rolling. J Immunol 151:6347\u20136357","journal-title":"J Immunol"},{"key":"3309_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1084\/jem.20040424","volume":"200","author":"ML Smith","year":"2004","unstructured":"Smith ML, Olson TS, Ley K (2004) CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo. J Exp Med 200:935\u2013939. https:\/\/doi.org\/10.1084\/jem.20040424","journal-title":"J Exp Med"},{"key":"3309_CR25","doi-asserted-by":"publisher","first-page":"35039","DOI":"10.1074\/jbc.M113.479113","volume":"288","author":"S Rajagopal","year":"2013","unstructured":"Rajagopal S, Bassoni DL, Campbell JJ et al (2013) Biased agonism as a mechanism for differential signaling by chemokine receptors. J Biol Chem 288:35039\u201335048. https:\/\/doi.org\/10.1074\/jbc.M113.479113","journal-title":"J Biol Chem"},{"key":"3309_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1126\/science.8316840","volume":"261","author":"D Wu","year":"1993","unstructured":"Wu D, LaRosa GJ, Simon MI (1993) G protein-coupled signal transduction pathways for interleukin-8. Science 261:101\u2013103. https:\/\/doi.org\/10.1126\/science.8316840","journal-title":"Science"},{"key":"3309_CR27","doi-asserted-by":"publisher","first-page":"17791","DOI":"10.1074\/jbc.M114.576827","volume":"289","author":"CR Surve","year":"2014","unstructured":"Surve CR, Lehmann D, Smrcka AV (2014) A chemical biology approach demonstrates g protein \u03b2\u03b3 subunits are sufficient to mediate directional neutrophil chemotaxis. J Biol Chem 289:17791\u201317801. https:\/\/doi.org\/10.1074\/jbc.M114.576827","journal-title":"J Biol Chem"},{"key":"3309_CR28","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1073\/pnas.93.13.6682","volume":"93","author":"SA Jones","year":"1996","unstructured":"Jones SA, Wolf M, Qin S et al (1996) Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci 93:6682\u20136686","journal-title":"Proc Natl Acad Sci"},{"key":"3309_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12964","author":"R Immler","year":"2018","unstructured":"Immler R, Simon SI, Sperandio M (2018) Calcium signalling and related ion channels in neutrophil recruitment and function. Eur J Clin Invest. https:\/\/doi.org\/10.1111\/eci.12964","journal-title":"Eur J Clin Invest"},{"key":"3309_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1189\/jlb.2MR1114-573R","volume":"98","author":"RA Clemens","year":"2015","unstructured":"Clemens RA, Lowell CA (2015) Store-operated calcium signaling in neutrophils. J Leukoc Biol 98:497\u2013502. https:\/\/doi.org\/10.1189\/jlb.2MR1114-573R","journal-title":"J Leukoc Biol"},{"key":"3309_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0092-8674(94)90237-2","volume":"77","author":"L Stephens","year":"1994","unstructured":"Stephens L, Smrcka A, Cooke FT et al (1994) A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein \u03b2\u03b3 subunits. Cell 77:83\u201393. https:\/\/doi.org\/10.1016\/0092-8674(94)90237-2","journal-title":"Cell"},{"key":"3309_CR32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1189\/jlb.0306227","volume":"80","author":"DF Smith","year":"2006","unstructured":"Smith DF, Deem TL, Bruce AC et al (2006) Leukocyte phosphoinositide-3 kinase gamma is required for chemokine-induced, sustained adhesion under flow in vivo. J Leukoc Biol 80:1491\u20131499. https:\/\/doi.org\/10.1189\/jlb.0306227","journal-title":"J Leukoc Biol"},{"key":"3309_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1189\/jlb.1112564","volume":"94","author":"L Gambardella","year":"2013","unstructured":"Gambardella L, Vermeren S (2013) Molecular players in neutrophil chemotaxis\u2014focus on PI3K and small GTPases. J Leukoc Biol 94:603\u2013612. https:\/\/doi.org\/10.1189\/jlb.1112564","journal-title":"J Leukoc Biol"},{"key":"3309_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00157","author":"CT Lefort","year":"2012","unstructured":"Lefort CT, Ley K (2012) Neutrophil arrest by LFA-1 activation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2012.00157","journal-title":"Front Immunol"},{"key":"3309_CR35","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.4049\/jimmunol.170.6.2904","volume":"170","author":"RM Richardson","year":"2003","unstructured":"Richardson RM, Marjoram RJ, Barak LS, Snyderman R (2003) Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J Immunol 170:2904\u20132911. https:\/\/doi.org\/10.4049\/jimmunol.170.6.2904","journal-title":"J Immunol"},{"key":"3309_CR36","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.4049\/jimmunol.1201114","volume":"189","author":"SK Raghuwanshi","year":"1950","unstructured":"Raghuwanshi SK, Su Y, Singh V et al (1950) (2012) The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol Baltim Md 189:2824\u20132832. https:\/\/doi.org\/10.4049\/jimmunol.1201114","journal-title":"J Immunol Baltim Md"},{"key":"3309_CR37","doi-asserted-by":"publisher","first-page":"16287","DOI":"10.1074\/jbc.274.23.16287","volume":"274","author":"J Barlic","year":"1999","unstructured":"Barlic J, Khandaker MH, Mahon E et al (1999) \u03b2-arrestins regulate Interleukin-8-induced CXCR1 Internalization. J Biol Chem 274:16287\u201316294. https:\/\/doi.org\/10.1074\/jbc.274.23.16287","journal-title":"J Biol Chem"},{"key":"3309_CR38","doi-asserted-by":"publisher","first-page":"24372","DOI":"10.1074\/jbc.M401364200","volume":"279","author":"JJ Rose","year":"2004","unstructured":"Rose JJ, Foley JF, Murphy PM, Venkatesan S (2004) On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. J Biol Chem 279:24372\u201324386. https:\/\/doi.org\/10.1074\/jbc.M401364200","journal-title":"J Biol Chem"},{"key":"3309_CR39","doi-asserted-by":"publisher","first-page":"23830","DOI":"10.1074\/jbc.273.37.23830","volume":"273","author":"RM Richardson","year":"1998","unstructured":"Richardson RM, Pridgen BC, Haribabu B et al (1998) Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2 Evidence for time-dependent signal generation. J Biol Chem 273:23830\u201323836. https:\/\/doi.org\/10.1074\/jbc.273.37.23830","journal-title":"J Biol Chem"},{"key":"3309_CR40","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.4049\/jimmunol.174.11.6927","volume":"174","author":"MW Nasser","year":"2005","unstructured":"Nasser MW, Marjoram RJ, Brown SL, Richardson RM (2005) Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-\u03b5. J Immunol 174:6927\u20136933. https:\/\/doi.org\/10.4049\/jimmunol.174.11.6927","journal-title":"J Immunol"},{"key":"3309_CR41","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1074\/jbc.273.17.10690","volume":"273","author":"RM Richardson","year":"1998","unstructured":"Richardson RM, Ali H, Pridgen BC et al (1998) Multiple signaling pathways of human interleukin-8 receptor a independent regulation by phosphorylation. J Biol Chem 273:10690\u201310695. https:\/\/doi.org\/10.1074\/jbc.273.17.10690","journal-title":"J Biol Chem"},{"key":"3309_CR42","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1073\/pnas.0636533100","volume":"100","author":"MA Lokuta","year":"2003","unstructured":"Lokuta MA, Nuzzi PA, Huttenlocher A (2003) Calpain regulates neutrophil chemotaxis. Proc Natl Acad Sci U S A 100:4006\u20134011. https:\/\/doi.org\/10.1073\/pnas.0636533100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3309_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.febslet.2010.11.031","volume":"585","author":"KM Henkels","year":"2011","unstructured":"Henkels KM, Frondorf K, Gonzalez-Mejia ME et al (2011) IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett 585:159\u2013166. https:\/\/doi.org\/10.1016\/j.febslet.2010.11.031","journal-title":"FEBS Lett"},{"key":"3309_CR44","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/intimm\/dxl064","volume":"18","author":"HC Lane","year":"2006","unstructured":"Lane HC, Anand AR, Ganju RK (2006) Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis. Int Immunol 18:1315\u20131325. https:\/\/doi.org\/10.1093\/intimm\/dxl064","journal-title":"Int Immunol"},{"key":"3309_CR45","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0165-6147(00)89032-X","volume":"16","author":"T Kenakin","year":"1995","unstructured":"Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232\u2013238. https:\/\/doi.org\/10.1016\/S0165-6147(00)89032-X","journal-title":"Trends Pharmacol Sci"},{"key":"3309_CR46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ejca.2006.01.006","volume":"42","author":"RM Strieter","year":"2006","unstructured":"Strieter RM, Burdick MD, Mestas J et al (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768\u2013778. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.006","journal-title":"Eur J Cancer"},{"key":"3309_CR47","first-page":"2151","volume":"45","author":"EL Becker","year":"1986","unstructured":"Becker EL, Kermode JC, Naccache PH et al (1986) Pertussis toxin as a probe of neutrophil activation. Fed Proc 45:2151\u20132155","journal-title":"Fed Proc"},{"key":"3309_CR48","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1084\/jem.20070846","volume":"205","author":"D Frommhold","year":"2008","unstructured":"Frommhold D, Ludwig A, Bixel MG et al (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. J Exp Med 205:1435\u20131446. https:\/\/doi.org\/10.1084\/jem.20070846","journal-title":"J Exp Med"},{"key":"3309_CR49","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/ncomms7915","volume":"6","author":"M Pruenster","year":"2015","unstructured":"Pruenster M, Kurz ARM, Chung K-J et al (2015) Extracellular MRP8\/14 is a regulator of \u03b22 integrin-dependent neutrophil slow rolling and adhesion. Nat Commun 6:6915. https:\/\/doi.org\/10.1038\/ncomms7915","journal-title":"Nat Commun"},{"key":"3309_CR50","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1021\/cr020474b","volume":"103","author":"Z Gao","year":"2003","unstructured":"Gao Z, Metz WA (2003) Unraveling the chemistry of chemokine receptor ligands. Chem Rev 103:3733\u20133752. https:\/\/doi.org\/10.1021\/cr020474b","journal-title":"Chem Rev"},{"key":"3309_CR51","doi-asserted-by":"publisher","first-page":"10095","DOI":"10.1074\/jbc.273.17.10095","volume":"273","author":"JR White","year":"1998","unstructured":"White JR, Lee JM, Young PR et al (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095\u201310098. https:\/\/doi.org\/10.1074\/jbc.273.17.10095","journal-title":"J Biol Chem"},{"key":"3309_CR52","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.169.11.6435","volume":"169","author":"PL Podolin","year":"2002","unstructured":"Podolin PL, Bolognese BJ, Foley JJ et al (2002) A potent and selective nonpeptide antagonist of cxcr2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169:6435\u20136444. https:\/\/doi.org\/10.4049\/jimmunol.169.11.6435","journal-title":"J Immunol"},{"key":"3309_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1476-5381.2009.00182.x","volume":"158","author":"M Bradley","year":"2009","unstructured":"Bradley M, Bond M, Manini J et al (2009) SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol 158:328\u2013338. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00182.x","journal-title":"Br J Pharmacol"},{"key":"3309_CR54","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2125.2011.03968.x","volume":"72","author":"AL Lazaar","year":"2011","unstructured":"Lazaar AL, Sweeney LE, MacDonald AJ et al (2011) SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 72:282\u2013293. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03968.x","journal-title":"Br J Clin Pharmacol"},{"key":"3309_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.imbio.2004.02.009","volume":"209","author":"SP Matzer","year":"2004","unstructured":"Matzer SP, Zombou J, Sarau HM et al (2004) A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 209:225\u2013233. https:\/\/doi.org\/10.1016\/j.imbio.2004.02.009","journal-title":"Immunobiology"},{"key":"3309_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1124\/jpet.117.240705","volume":"362","author":"J Busch-Petersen","year":"2017","unstructured":"Busch-Petersen J, Carpenter DC, Burman M et al (2017) Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2. J Pharmacol Exp Ther 362:338\u2013346. https:\/\/doi.org\/10.1124\/jpet.117.240705","journal-title":"J Pharmacol Exp Ther"},{"key":"3309_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0017-x","author":"BE Miller","year":"2015","unstructured":"Miller BE, Mistry S, Smart K et al (2015) The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) \u2212 a selective CXCR2 antagonist \u2212 in healthy adult subjects. BMC Pharmacol Toxicol. https:\/\/doi.org\/10.1186\/s40360-015-0017-x","journal-title":"BMC Pharmacol Toxicol"},{"key":"3309_CR58","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00583-2020","author":"HR Keir","year":"2020","unstructured":"Keir HR, Richardson H, Fillmore C et al (2020) CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00583-2020","journal-title":"ERJ Open Res"},{"key":"3309_CR59","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1021\/jm500827t","volume":"57","author":"DY Maeda","year":"2014","unstructured":"Maeda DY, Peck AM, Schuler AD et al (2014) Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2. J Med Chem 57:8378\u20138397. https:\/\/doi.org\/10.1021\/jm500827t","journal-title":"J Med Chem"},{"key":"3309_CR60","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.bmcl.2015.04.041","volume":"25","author":"DY Maeda","year":"2015","unstructured":"Maeda DY, Peck AM, Schuler AD et al (2015) Boronic acid-containing CXCR1\/2 antagonists: optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorg Med Chem Lett 25:2280\u20132284. https:\/\/doi.org\/10.1016\/j.bmcl.2015.04.041","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR61","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.bmcl.2015.07.090","volume":"25","author":"AD Schuler","year":"2015","unstructured":"Schuler AD, Engles CA, Maeda DY et al (2015) Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1\/2 Antagonists: optimization of aqueous solubility and oral bioavailability. Bioorg Med Chem Lett 25:3793\u20133797. https:\/\/doi.org\/10.1016\/j.bmcl.2015.07.090","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR62","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","volume":"26","author":"S Greene","year":"2020","unstructured":"Greene S, Robbins Y, Mydlarz WK et al (2020) Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-Cell immunotherapy in head and neck cancer models. Clin Cancer Res 26:1420\u20131431. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2625","journal-title":"Clin Cancer Res"},{"key":"3309_CR63","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126853","author":"L Sun","year":"2019","unstructured":"Sun L, Clavijo PE, Robbins Y et al (2019) Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.126853","journal-title":"JCI Insight"},{"key":"3309_CR64","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu X, Horner JW, Paul E et al (2017) Effective combinatorial immunotherapy for castration resistant prostate cancer. Nature 543:728\u2013732. https:\/\/doi.org\/10.1038\/nature21676","journal-title":"Nature"},{"key":"3309_CR65","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/ijms21072367","volume":"21","author":"V Petrova","year":"2020","unstructured":"Petrova V, Arkhypov I, Weber R et al (2020) Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Int J Mol Sci 21:2367. https:\/\/doi.org\/10.3390\/ijms21072367","journal-title":"Int J Mol Sci"},{"key":"3309_CR66","doi-asserted-by":"publisher","first-page":"11791","DOI":"10.1073\/pnas.0402090101","volume":"101","author":"R Bertini","year":"2004","unstructured":"Bertini R, Allegretti M, Bizzarri C et al (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101:11791\u201311796. https:\/\/doi.org\/10.1073\/pnas.0402090101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3309_CR67","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2337\/db14-0443","volume":"64","author":"A Citro","year":"2015","unstructured":"Citro A, Valle A, Cantarelli E et al (2015) CXCR1\/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes 64:1329\u20131340. https:\/\/doi.org\/10.2337\/db14-0443","journal-title":"Diabetes"},{"key":"3309_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sc.2010.127","volume":"49","author":"DR Marsh","year":"2011","unstructured":"Marsh DR, Flemming JMP (2011) Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury. Spinal Cord 49:337\u2013344. https:\/\/doi.org\/10.1038\/sc.2010.127","journal-title":"Spinal Cord"},{"key":"3309_CR69","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1172\/JCI63089","volume":"122","author":"A Citro","year":"2012","unstructured":"Citro A, Cantarelli E, Maffi P et al (2012) CXCR1\/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 122:3647\u20133651. https:\/\/doi.org\/10.1172\/JCI63089","journal-title":"J Clin Invest"},{"key":"3309_CR70","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2337\/dc19-1480","volume":"43","author":"P Maffi","year":"2020","unstructured":"Maffi P, Lundgren T, Tufveson G et al (2020) Targeting CXCR1\/2 does not improve insulin secretion after pancreatic Islet transplantation: a phase 3, double-blind, randomized, placebo-controlled trial in type 1 diabetes. Diabetes Care 43:710\u2013718. https:\/\/doi.org\/10.2337\/dc19-1480","journal-title":"Diabetes Care"},{"key":"3309_CR71","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-021-06367-5","volume":"190","author":"LJ Goldstein","year":"2021","unstructured":"Goldstein LJ, Mansutti M, Levy C et al (2021) A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Res Treat 190:265\u2013275. https:\/\/doi.org\/10.1007\/s10549-021-06367-5","journal-title":"Breast Cancer Res Treat"},{"key":"3309_CR72","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40121-022-00644-6","volume":"11","author":"G Landoni","year":"2022","unstructured":"Landoni G, Piemonti L, d\u2019Arminio MA et al (2022) A multicenter phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with COVID-19 pneumonia. Infect Dis Ther 11:1559\u20131574. https:\/\/doi.org\/10.1007\/s40121-022-00644-6","journal-title":"Infect Dis Ther"},{"key":"3309_CR73","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/sj.bjp.0707462","volume":"153","author":"MM Barsante","year":"2008","unstructured":"Barsante MM, Cunha TM, Allegretti M et al (2008) Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br J Pharmacol 153:992\u20131002. https:\/\/doi.org\/10.1038\/sj.bjp.0707462","journal-title":"Br J Pharmacol"},{"key":"3309_CR74","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/bjp.2008.94","volume":"154","author":"TM Cunha","year":"2008","unstructured":"Cunha TM, Barsante MM, Guerrero AT et al (2008) Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1\/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br J Pharmacol 154:460\u2013470. https:\/\/doi.org\/10.1038\/bjp.2008.94","journal-title":"Br J Pharmacol"},{"key":"3309_CR75","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1165\/rcmb.2007-0364OC","volume":"40","author":"RC Russo","year":"2009","unstructured":"Russo RC, Guabiraba R, Garcia CC et al (2009) Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 40:410\u2013421. https:\/\/doi.org\/10.1165\/rcmb.2007-0364OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3309_CR76","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1476-5381.2011.01566.x","volume":"165","author":"R Bertini","year":"2012","unstructured":"Bertini R, Barcelos LS, Beccari AR et al (2012) Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1\/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 165:436\u2013454. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01566.x","journal-title":"Br J Pharmacol"},{"key":"3309_CR77","first-page":"35","volume":"17","author":"A Garau","year":"2006","unstructured":"Garau A, Bertini R, Mosca M et al (2006) Development of a systemically-active dual CXCR1\/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 17:35\u201341","journal-title":"Eur Cytokine Netw"},{"key":"3309_CR78","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3390\/cells10092324","volume":"10","author":"V Castelli","year":"2021","unstructured":"Castelli V, Brandolini L, d\u2019Angelo M et al (2021) CXCR1\/2 Inhibitor ladarixin ameliorates the insulin resistance of 3T3-L1 Adipocytes by Inhibiting Inflammation and Improving Insulin Signaling. Cells 10:2324. https:\/\/doi.org\/10.3390\/cells10092324","journal-title":"Cells"},{"key":"3309_CR79","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/dom.14770","volume":"24","author":"L Piemonti","year":"2022","unstructured":"Piemonti L, Keymeulen B, Gillard P et al (2022) Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 24:1840\u20131849. https:\/\/doi.org\/10.1111\/dom.14770","journal-title":"Diabetes Obes Metab"},{"key":"3309_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.phrs.2015.11.005","volume":"103","author":"AH Lopes","year":"2016","unstructured":"Lopes AH, Brandolini L, Aramini A et al (2016) DF2755A, a novel non-competitive allosteric inhibitor of CXCR1\/2, reduces inflammatory and post-operative pain. Pharmacol Res 103:69\u201379. https:\/\/doi.org\/10.1016\/j.phrs.2015.11.005","journal-title":"Pharmacol Res"},{"key":"3309_CR81","doi-asserted-by":"publisher","first-page":"854238","DOI":"10.3389\/fphar.2022.854238","volume":"13","author":"L Brandolini","year":"2022","unstructured":"Brandolini L, Aramini A, Bianchini G et al (2022) Inflammation-independent antinociceptive effects of DF2755A, a CXCR1\/2 selective inhibitor: a new potential therapeutic treatment for peripheral neuropathy associated to non-ulcerative interstitial cystitis\/bladder pain syndrome. Front Pharmacol 13:854238. https:\/\/doi.org\/10.3389\/fphar.2022.854238","journal-title":"Front Pharmacol"},{"key":"3309_CR82","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/jpet.106.119040","volume":"322","author":"RW Chapman","year":"2007","unstructured":"Chapman RW, Minnicozzi M, Celly CS et al (2007) A novel, orally active CXCR1\/2 receptor antagonist, Sch 527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322:486\u2013493. https:\/\/doi.org\/10.1124\/jpet.106.119040","journal-title":"J Pharmacol Exp Ther"},{"key":"3309_CR83","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1124\/jpet.106.118927","volume":"322","author":"W Gonsiorek","year":"2007","unstructured":"Gonsiorek W, Fan X, Hesk D et al (2007) Pharmacological characterization of Sch527123, a potent allosteric CXCR1\/CXCR2 antagonist. J Pharmacol Exp Ther 322:477\u2013485. https:\/\/doi.org\/10.1124\/jpet.106.118927","journal-title":"J Pharmacol Exp Ther"},{"key":"3309_CR84","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/09031936.00048509","volume":"35","author":"O Holz","year":"2010","unstructured":"Holz O, Khalilieh S, Ludwig-Sengpiel A et al (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 35:564\u2013570. https:\/\/doi.org\/10.1183\/09031936.00048509","journal-title":"Eur Respir J"},{"key":"3309_CR85","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ajpath.2020.12.013","volume":"191","author":"HK Ashar","year":"2021","unstructured":"Ashar HK, Pulavendran S, Rudd JM et al (2021) Administration of a CXC chemokine receptor 2 (CXCR2) antagonist, SCH527123, together with oseltamivir suppresses NETosis and protects mice from lethal influenza and piglets from swine-influenza infection. Am J Pathol 191:669\u2013685. https:\/\/doi.org\/10.1016\/j.ajpath.2020.12.013","journal-title":"Am J Pathol"},{"key":"3309_CR86","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/1535-7163.MCT-11-0915","volume":"11","author":"Y Ning","year":"2012","unstructured":"Ning Y, Labonte MJ, Zhang W et al (2012) The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther 11:1353\u20131364. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0915","journal-title":"Mol Cancer Ther"},{"key":"3309_CR87","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","volume":"191","author":"SI Rennard","year":"2015","unstructured":"Rennard SI, Dale DC, Donohue JF et al (2015) CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191:1001\u20131011. https:\/\/doi.org\/10.1164\/rccm.201405-0992OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3309_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pharmthera.2008.10.005","volume":"121","author":"RW Chapman","year":"2009","unstructured":"Chapman RW, Phillips JE, Hipkin RW et al (2009) CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121:55\u201368. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.10.005","journal-title":"Pharmacol Ther"},{"key":"3309_CR89","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1465-9921-14-137","volume":"14","author":"BR Leaker","year":"2013","unstructured":"Leaker BR, Barnes PJ, O\u2019Connor B (2013) Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res 14:137. https:\/\/doi.org\/10.1186\/1465-9921-14-137","journal-title":"Respir Res"},{"key":"3309_CR90","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.pan.2016.07.005","volume":"16","author":"SR Malla","year":"2016","unstructured":"Malla SR, K\u00e4rrman M\u00e5rdh C, G\u00fcnther A et al (2016) Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology 16:761\u2013769. https:\/\/doi.org\/10.1016\/j.pan.2016.07.005","journal-title":"Pancreatology"},{"key":"3309_CR91","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/jpet.114.221358","volume":"353","author":"DJ Nicholls","year":"2015","unstructured":"Nicholls DJ, Wiley K, Dainty I et al (2015) Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther 353:340\u2013350. https:\/\/doi.org\/10.1124\/jpet.114.221358","journal-title":"J Pharmacol Exp Ther"},{"key":"3309_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-018-0236-x","volume":"18","author":"M Cullberg","year":"2018","unstructured":"Cullberg M, Arfvidsson C, Larsson B et al (2018) Pharmacokinetics of the oral selective CXCR2 antagonist AZD5069: a summary of eight phase i studies in healthy volunteers. Drugs RD 18:149\u2013159. https:\/\/doi.org\/10.1007\/s40268-018-0236-x","journal-title":"Drugs RD"},{"key":"3309_CR93","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M et al (2016) Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 4:797\u2013806. https:\/\/doi.org\/10.1016\/S2213-2600(16)30227-2","journal-title":"Lancet Respir Med"},{"key":"3309_CR94","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","volume":"31","author":"AM Kirsten","year":"2015","unstructured":"Kirsten AM, F\u00f6rster K, Radeczky E et al (2015) The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther 31:36\u201341. https:\/\/doi.org\/10.1016\/j.pupt.2015.02.001","journal-title":"Pulm Pharmacol Ther"},{"key":"3309_CR95","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.12724","volume":"80","author":"S Jurcevic","year":"2015","unstructured":"Jurcevic S, Humfrey C, Uddin M et al (2015) The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol 80:1324\u20131336. https:\/\/doi.org\/10.1111\/bcp.12724","journal-title":"Br J Clin Pharmacol"},{"key":"3309_CR96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/ijc.25987","volume":"129","author":"S Tazzyman","year":"2011","unstructured":"Tazzyman S, Barry ST, Ashton S et al (2011) Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer 129:847\u2013858. https:\/\/doi.org\/10.1002\/ijc.25987","journal-title":"Int J Cancer"},{"key":"3309_CR97","doi-asserted-by":"publisher","first-page":"814","DOI":"10.4049\/jimmunol.154.2.814","volume":"154","author":"S Hayashi","year":"1995","unstructured":"Hayashi S, Kurdowska A, Miller EJ et al (1995) Synthetic hexa- and heptapeptides that inhibit IL-8 from binding to and activating human blood neutrophils. J Immunol 154:814\u2013824","journal-title":"J Immunol"},{"key":"3309_CR98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00408-002-0106-7","volume":"180","author":"S Hayashi","year":"2002","unstructured":"Hayashi S, Yatsunami J, Fukuno Y et al (2002) Antileukinate, a hexapeptide inhibitor of CXC-chemokine receptor, suppresses bleomycin-induced acute lung injury in mice. Lung 180:339\u2013348. https:\/\/doi.org\/10.1007\/s00408-002-0106-7","journal-title":"Lung"},{"key":"3309_CR99","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nm1361","volume":"12","author":"NM Weathington","year":"2006","unstructured":"Weathington NM, van Houwelingen AH, Noerager BD et al (2006) A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12:317\u2013323. https:\/\/doi.org\/10.1038\/nm1361","journal-title":"Nat Med"},{"key":"3309_CR100","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejphar.2011.02.045","volume":"668","author":"PL Jackson","year":"2011","unstructured":"Jackson PL, Noerager BD, Jablonsky MJ et al (2011) A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline. Eur J Pharmacol 668:435\u2013442. https:\/\/doi.org\/10.1016\/j.ejphar.2011.02.045","journal-title":"Eur J Pharmacol"},{"key":"3309_CR101","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1006\/bbrc.2001.5423","volume":"286","author":"F Li","year":"2001","unstructured":"Li F, Gordon JR (2001) IL-8(3\u201373)K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun 286:595\u2013600. https:\/\/doi.org\/10.1006\/bbrc.2001.5423","journal-title":"Biochem Biophys Res Commun"},{"key":"3309_CR102","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0006-291X(02)00318-2","volume":"293","author":"F Li","year":"2002","unstructured":"Li F, Zhang X, Gordon JR (2002) CXCL8(3\u201373)K11R\/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8\/IL-8. Biochem Biophys Res Commun 293:939\u2013944. https:\/\/doi.org\/10.1016\/S0006-291X(02)00318-2","journal-title":"Biochem Biophys Res Commun"},{"key":"3309_CR103","doi-asserted-by":"publisher","first-page":"e720975","DOI":"10.1155\/2013\/720975","volume":"2013","author":"J Wei","year":"2013","unstructured":"Wei J, Peng J, Wang B et al (2013) CXCR1\/CXCR2 antagonism is effective in pulmonary defense against klebsiella pneumoniae infection. BioMed Res Int 2013:e720975. https:\/\/doi.org\/10.1155\/2013\/720975","journal-title":"BioMed Res Int"},{"key":"3309_CR104","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1073\/pnas.022460899","volume":"99","author":"L Covic","year":"2002","unstructured":"Covic L, Gresser AL, Talavera J et al (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci 99:643\u2013648. https:\/\/doi.org\/10.1073\/pnas.022460899","journal-title":"Proc Natl Acad Sci"},{"key":"3309_CR105","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nm1245","volume":"11","author":"NC Kaneider","year":"2005","unstructured":"Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 11:661\u2013665. https:\/\/doi.org\/10.1038\/nm1245","journal-title":"Nat Med"},{"key":"3309_CR106","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/gutjnl-2015-310344","volume":"66","author":"V Wieser","year":"2017","unstructured":"Wieser V, Adolph TE, Enrich B et al (2017) Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors. Gut 66:930\u2013938. https:\/\/doi.org\/10.1136\/gutjnl-2015-310344","journal-title":"Gut"},{"key":"3309_CR107","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1016\/j.bmcl.2014.06.011","volume":"24","author":"DW Porter","year":"2014","unstructured":"Porter DW, Bradley M, Brown Z et al (2014) The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists. Bioorg Med Chem Lett 24:3285\u20133290. https:\/\/doi.org\/10.1016\/j.bmcl.2014.06.011","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR108","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bmcl.2013.11.074","volume":"24","author":"DW Porter","year":"2014","unstructured":"Porter DW, Bradley M, Brown Z et al (2014) The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett 24:72\u201376. https:\/\/doi.org\/10.1016\/j.bmcl.2013.11.074","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR109","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1016\/S0968-0896(03)00399-7","volume":"11","author":"JJ Li","year":"2003","unstructured":"Li JJ, Carson KG, Trivedi BK et al (2003) Synthesis and structure\u2013Activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-Molecule antagonists for interleukin-8 receptor. Bioorg Med Chem 11:3777\u20133790. https:\/\/doi.org\/10.1016\/S0968-0896(03)00399-7","journal-title":"Bioorg Med Chem"},{"key":"3309_CR110","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0960-894X(02)00188-9","volume":"12","author":"NS Cutshall","year":"2002","unstructured":"Cutshall NS, Kucera KA, Ursino R et al (2002) Nicotinanilides as inhibitors of neutrophil chemotaxis. Bioorg Med Chem Lett 12:1517\u20131520. https:\/\/doi.org\/10.1016\/S0960-894X(02)00188-9","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR111","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/S0960-894X(01)00326-2","volume":"11","author":"NS Cutshall","year":"2001","unstructured":"Cutshall NS, Ursino R, Kucera KA et al (2001) Nicotinamide N-oxides as CXCR2 antagonists. Bioorg Med Chem Lett 11:1951\u20131954. https:\/\/doi.org\/10.1016\/S0960-894X(01)00326-2","journal-title":"Bioorg Med Chem Lett"},{"key":"3309_CR112","doi-asserted-by":"publisher","first-page":"18638","DOI":"10.1038\/srep18638","volume":"5","author":"S-J Jiang","year":"2015","unstructured":"Jiang S-J, Liou J-W, Chang C-C et al (2015) Peptides derived from CXCL8 based on in silico analysis inhibit CXCL8 interactions with its receptor CXCR1. Sci Rep 5:18638. https:\/\/doi.org\/10.1038\/srep18638","journal-title":"Sci Rep"},{"key":"3309_CR113","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB et al (2017) Ulcerative colitis. The Lancet 389:1756\u20131770. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2","journal-title":"The Lancet"},{"key":"3309_CR114","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharmthera.2006.04.002","volume":"112","author":"C Bizzarri","year":"2006","unstructured":"Bizzarri C, Beccari AR, Bertini R et al (2006) ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112:139\u2013149. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.04.002","journal-title":"Pharmacol Ther"},{"key":"3309_CR115","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/gutjnl-2012-303252","volume":"63","author":"PJ Koelink","year":"2014","unstructured":"Koelink PJ, Overbeek SA, Braber S et al (2014) Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 63:578\u2013587. https:\/\/doi.org\/10.1136\/gutjnl-2012-303252","journal-title":"Gut"},{"key":"3309_CR116","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/00365521.2016.1235224","volume":"52","author":"D Muthas","year":"2017","unstructured":"Muthas D, Reznichenko A, Balendran CA et al (2017) Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 52:125\u2013135. https:\/\/doi.org\/10.1080\/00365521.2016.1235224","journal-title":"Scand J Gastroenterol"},{"key":"3309_CR117","first-page":"77","volume":"39","author":"WGW Pathirana","year":"2018","unstructured":"Pathirana WGW, Chubb SP, Gillett MJ, Vasikaran SD (2018) Faecal Calprotectin. Clin Biochem Rev 39:77\u201390","journal-title":"Clin Biochem Rev"},{"key":"3309_CR118","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1124\/jpet.108.145862","volume":"329","author":"SM Farooq","year":"2009","unstructured":"Farooq SM, Stillie R, Svensson M et al (2009) Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 329:123\u2013129. https:\/\/doi.org\/10.1124\/jpet.108.145862","journal-title":"J Pharmacol Exp Ther"},{"key":"3309_CR119","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1189\/jlb.0207118","volume":"82","author":"P Buanne","year":"2007","unstructured":"Buanne P, Carlo ED, Caputi L et al (2007) Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 82:1239\u20131246. https:\/\/doi.org\/10.1189\/jlb.0207118","journal-title":"J Leukoc Biol"},{"key":"3309_CR120","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1189\/jlb.0408231","volume":"84","author":"AF Bento","year":"2008","unstructured":"Bento AF, Leite DFP, Claudino RF et al (2008) The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol 84:1213\u20131221. https:\/\/doi.org\/10.1189\/jlb.0408231","journal-title":"J Leukoc Biol"},{"key":"3309_CR121","first-page":"8561","volume":"13","author":"JDC Mello","year":"2021","unstructured":"Mello JDC, Gomes LEM, Silva JF et al (2021) The role of chemokines and adipokines as biomarkers of Crohn\u2019s disease activity: a systematic review of the literature. Am J Transl Res 13:8561\u20138574","journal-title":"Am J Transl Res"},{"key":"3309_CR122","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jcmgh.2021.03.002","volume":"12","author":"B Drury","year":"2021","unstructured":"Drury B, Hardisty G, Gray RD, Ho G-T (2021) Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation. Cell Mol Gastroenterol Hepatol 12:321\u2013333. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.03.002","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3309_CR123","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","volume":"4","author":"HK Seitz","year":"2018","unstructured":"Seitz HK, Bataller R, Cortez-Pinto H et al (2018) Alcoholic liver disease. Nat Rev Dis Primer 4:16. https:\/\/doi.org\/10.1038\/s41572-018-0014-7","journal-title":"Nat Rev Dis Primer"},{"key":"3309_CR124","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bpg.2010.07.003","volume":"24","author":"F Stickel","year":"2010","unstructured":"Stickel F, Seitz HK (2010) Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 24:683\u2013693. https:\/\/doi.org\/10.1016\/j.bpg.2010.07.003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3309_CR125","doi-asserted-by":"publisher","first-page":"G1188","DOI":"10.1152\/ajpgi.2001.281.5.G1188","volume":"281","author":"ML Bajt","year":"2001","unstructured":"Bajt ML, Farhood A, Jaeschke H (2001) Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am J Physiol-Gastrointest Liver Physiol 281:G1188\u2013G1195. https:\/\/doi.org\/10.1152\/ajpgi.2001.281.5.G1188","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3309_CR126","doi-asserted-by":"publisher","first-page":"e98259","DOI":"10.1371\/journal.pone.0098259","volume":"9","author":"M Shen","year":"2014","unstructured":"Shen M, Hu P, Donskov F et al (2014) Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS ONE 9:e98259. https:\/\/doi.org\/10.1371\/journal.pone.0098259","journal-title":"PLoS ONE"},{"key":"3309_CR127","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1158\/1078-0432.CCR-03-0760","volume":"10","author":"JED Larco","year":"2004","unstructured":"Larco JED, Wuertz BRK, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895\u20134900. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0760","journal-title":"Clin Cancer Res"},{"key":"3309_CR128","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10585-014-9691-0","volume":"32","author":"B Sharma","year":"2015","unstructured":"Sharma B, Nannuru KC, Varney ML, Singh RK (2015) Host Cxcr2-dependent regulation of mammary tumor growth and metastasis. Clin Exp Metastasis 32:65\u201372. https:\/\/doi.org\/10.1007\/s10585-014-9691-0","journal-title":"Clin Exp Metastasis"},{"key":"3309_CR129","doi-asserted-by":"publisher","first-page":"e000308","DOI":"10.1136\/jitc-2019-000308","volume":"8","author":"M Zhang","year":"2020","unstructured":"Zhang M, Huang L, Ding G et al (2020) Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. J Immunother Cancer 8:e000308. https:\/\/doi.org\/10.1136\/jitc-2019-000308","journal-title":"J Immunother Cancer"},{"key":"3309_CR130","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.7150\/thno.22536","volume":"8","author":"MM-H Yung","year":"2018","unstructured":"Yung MM-H, Tang HW-M, Cai PC-H et al (2018) GRO-\u03b1 and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1\/NF\u03baB signaling cascade. Theranostics 8:1270\u20131285. https:\/\/doi.org\/10.7150\/thno.22536","journal-title":"Theranostics"},{"key":"3309_CR131","doi-asserted-by":"publisher","first-page":"e83789","DOI":"10.1371\/journal.pone.0083789","volume":"8","author":"Y-L Dong","year":"2013","unstructured":"Dong Y-L, Kabir SM, Lee E-S, Son D-S (2013) CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-\u03baB activation via EGFR-transactivated Akt signaling. PLoS ONE 8:e83789. https:\/\/doi.org\/10.1371\/journal.pone.0083789","journal-title":"PLoS ONE"},{"key":"3309_CR132","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.cell.2008.03.038","volume":"133","author":"JC Acosta","year":"2008","unstructured":"Acosta JC, O\u2019Loghlen A, Banito A et al (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133:1006\u20131018. https:\/\/doi.org\/10.1016\/j.cell.2008.03.038","journal-title":"Cell"},{"key":"3309_CR133","first-page":"4285","volume":"57","author":"PM O\u2019Connor","year":"1997","unstructured":"O\u2019Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285\u20134300","journal-title":"Cancer Res"},{"key":"3309_CR134","doi-asserted-by":"publisher","first-page":"16472","DOI":"10.1073\/pnas.0605752103","volume":"103","author":"G Yang","year":"2006","unstructured":"Yang G, Rosen DG, Zhang Z et al (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103:16472\u201316477. https:\/\/doi.org\/10.1073\/pnas.0605752103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3309_CR135","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/cancers12020459","volume":"12","author":"C-C Chao","year":"2020","unstructured":"Chao C-C, Lee C-W, Chang T-M et al (2020) CXCL1\/CXCR2 paracrine axis contributes to lung metastasis in osteosarcoma. Cancers 12:459. https:\/\/doi.org\/10.3390\/cancers12020459","journal-title":"Cancers"},{"key":"3309_CR136","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/ijms20051237","volume":"20","author":"B Sharma","year":"2019","unstructured":"Sharma B, Nannuru KC, Saxena S et al (2019) CXCR2: a novel mediator of mammary tumor bone metastasis. Int J Mol Sci 20:1237. https:\/\/doi.org\/10.3390\/ijms20051237","journal-title":"Int J Mol Sci"},{"key":"3309_CR137","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.4049\/jimmunol.165.9.5269","volume":"165","author":"CL Addison","year":"1950","unstructured":"Addison CL, Daniel TO, Burdick MD et al (1950) (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol Baltim Md 165:5269\u20135277. https:\/\/doi.org\/10.4049\/jimmunol.165.9.5269","journal-title":"J Immunol Baltim Md"},{"key":"3309_CR138","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/labinvest.2013.71","volume":"93","author":"M Miyake","year":"2013","unstructured":"Miyake M, Goodison S, Urquidi V et al (2013) Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1\/2 and EGF pathways. Lab Investig J Tech Methods Pathol 93:768\u2013778. https:\/\/doi.org\/10.1038\/labinvest.2013.71","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"3309_CR139","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/onc.2017.108","volume":"36","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Zhou Z-J, Xia G-K et al (2017) A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene 36:5122\u20135133. https:\/\/doi.org\/10.1038\/onc.2017.108","journal-title":"Oncogene"},{"key":"3309_CR140","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1158\/1078-0432.CCR-18-3567","volume":"25","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Xia G, Xiang Z et al (2019) A C-X-C chemokine receptor type 2-dominated cross-talk between tumor cells and macrophages drives gastric cancer metastasis. Clin Cancer Res Off J Am Assoc Cancer Res 25:3317\u20133328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3567","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3309_CR141","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12885-015-1793-9","volume":"15","author":"Z Wang","year":"2015","unstructured":"Wang Z, Liu H, Shen Z et al (2015) The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients. BMC Cancer 15:766. https:\/\/doi.org\/10.1186\/s12885-015-1793-9","journal-title":"BMC Cancer"},{"key":"3309_CR142","doi-asserted-by":"publisher","first-page":"e0178635","DOI":"10.1371\/journal.pone.0178635","volume":"12","author":"H Kasashima","year":"2017","unstructured":"Kasashima H, Yashiro M, Nakamae H et al (2017) Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma. PLoS ONE 12:e0178635. https:\/\/doi.org\/10.1371\/journal.pone.0178635","journal-title":"PLoS ONE"},{"key":"3309_CR143","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.surg.2013.12.037","volume":"155","author":"H Sueoka","year":"2014","unstructured":"Sueoka H, Hirano T, Uda Y et al (2014) Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma. Surgery 155:640\u2013649. https:\/\/doi.org\/10.1016\/j.surg.2013.12.037","journal-title":"Surgery"},{"key":"3309_CR144","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12032-015-0703-y","volume":"32","author":"D Dabkeviciene","year":"2015","unstructured":"Dabkeviciene D, Jonusiene V, Zitkute V et al (2015) The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. Med Oncol 32:258. https:\/\/doi.org\/10.1007\/s12032-015-0703-y","journal-title":"Med Oncol"},{"key":"3309_CR145","doi-asserted-by":"publisher","first-page":"28442","DOI":"10.18632\/oncotarget.16086","volume":"8","author":"J Zhao","year":"2017","unstructured":"Zhao J, Ou B, Feng H et al (2017) Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer. Oncotarget 8:28442\u201328454. https:\/\/doi.org\/10.18632\/oncotarget.16086","journal-title":"Oncotarget"},{"key":"3309_CR146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1593\/tlo.10184","volume":"4","author":"A Li","year":"2011","unstructured":"Li A, Cheng XJ, Moro A et al (2011) CXCR2-dependent endothelial progenitor cell mobilization in pancreatic cancer growth. Transl Oncol 4:20\u201328","journal-title":"Transl Oncol"},{"key":"3309_CR147","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29:832\u2013845. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.014","journal-title":"Cancer Cell"},{"key":"3309_CR148","doi-asserted-by":"publisher","first-page":"13988","DOI":"10.1073\/pnas.2335921100","volume":"100","author":"JED Larco","year":"2003","unstructured":"Larco JED, Wuertz BRK, Yee D et al (2003) Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc Natl Acad Sci 100:13988\u201313993. https:\/\/doi.org\/10.1073\/pnas.2335921100","journal-title":"Proc Natl Acad Sci"},{"key":"3309_CR149","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/pros.20476","volume":"66","author":"H Shen","year":"2006","unstructured":"Shen H, Schuster R, Lu B et al (2006) Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66:1721\u20131728. https:\/\/doi.org\/10.1002\/pros.20476","journal-title":"Prostate"},{"key":"3309_CR150","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cyto.2010.10.008","volume":"53","author":"P Bakshi","year":"2011","unstructured":"Bakshi P, Margenthaler E, Reed J et al (2011) Depletion of CXCR2 inhibits \u03b3-secretase activity and amyloid-\u03b2 production in a murine model of Alzheimer\u2019s disease. Cytokine 53:163\u2013169. https:\/\/doi.org\/10.1016\/j.cyto.2010.10.008","journal-title":"Cytokine"},{"key":"3309_CR151","doi-asserted-by":"publisher","first-page":"154785","DOI":"10.1016\/j.cyto.2019.154785","volume":"123","author":"C Yu","year":"2019","unstructured":"Yu C, Zhang Y (2019) Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine 123:154785. https:\/\/doi.org\/10.1016\/j.cyto.2019.154785","journal-title":"Cytokine"},{"key":"3309_CR152","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3390\/cancers13112584","volume":"13","author":"C Timaxian","year":"2021","unstructured":"Timaxian C, Vogel CFA, Orcel C et al (2021) Pivotal role for cxcr2 in regulating tumor-associated neutrophil in breast cancer. Cancers 13:2584. https:\/\/doi.org\/10.3390\/cancers13112584","journal-title":"Cancers"},{"key":"3309_CR153","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/cancers13102328","volume":"13","author":"F Boissi\u00e8re-Michot","year":"2021","unstructured":"Boissi\u00e8re-Michot F, Jacot W, Massol O et al (2021) CXCR2 levels correlate with immune infiltration and a better prognosis of triple-negative breast cancers. Cancers 13:2328. https:\/\/doi.org\/10.3390\/cancers13102328","journal-title":"Cancers"},{"key":"3309_CR154","doi-asserted-by":"publisher","first-page":"601206","DOI":"10.3389\/fmolb.2020.601206","volume":"7","author":"Z Wu","year":"2020","unstructured":"Wu Z, Zhang Y, Chen X et al (2020) Characterization of the prognostic values of the CXCR1\u20137 in clear cell renal cell carcinoma (ccRCC) microenvironment. Front Mol Biosci 7:601206. https:\/\/doi.org\/10.3389\/fmolb.2020.601206","journal-title":"Front Mol Biosci"},{"key":"3309_CR155","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1517\/14728221003652471","volume":"14","author":"B Sharma","year":"2010","unstructured":"Sharma B, Singh S, Varney ML, Singh RK (2010) Targeting CXCR1\/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 14:435\u2013442. https:\/\/doi.org\/10.1517\/14728221003652471","journal-title":"Expert Opin Ther Targets"},{"key":"3309_CR156","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1158\/1078-0432.CCR-08-2387","volume":"15","author":"S Singh","year":"2009","unstructured":"Singh S, Sadanandam A, Nannuru KC et al (2009) Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res Off J Am Assoc Cancer Res 15:2380\u20132386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2387","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3309_CR157","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1172\/JCI39397","volume":"120","author":"C Ginestier","year":"2010","unstructured":"Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485\u2013497. https:\/\/doi.org\/10.1172\/JCI39397","journal-title":"J Clin Invest"},{"key":"3309_CR158","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2010.10.004","volume":"300","author":"ML Varney","year":"2011","unstructured":"Varney ML, Singh S, Li A et al (2011) Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 300:180\u2013188. https:\/\/doi.org\/10.1016\/j.canlet.2010.10.004","journal-title":"Cancer Lett"},{"key":"3309_CR159","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1620\/tjem.228.147","volume":"228","author":"X Liu","year":"2012","unstructured":"Liu X, Peng J, Sun W et al (2012) G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp Med 228:147\u2013156. https:\/\/doi.org\/10.1620\/tjem.228.147","journal-title":"Tohoku J Exp Med"},{"key":"3309_CR160","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","volume":"6","author":"A Sparmann","year":"2004","unstructured":"Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447\u2013458. https:\/\/doi.org\/10.1016\/j.ccr.2004.09.028","journal-title":"Cancer Cell"},{"key":"3309_CR161","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.7150\/thno.34681","volume":"9","author":"M Dufies","year":"2019","unstructured":"Dufies M, Grytsai O, Ronco C et al (2019) New CXCR1\/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments. Theranostics 9:5332\u20135346. https:\/\/doi.org\/10.7150\/thno.34681","journal-title":"Theranostics"},{"key":"3309_CR162","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","volume":"4","author":"T Chao","year":"2016","unstructured":"Chao T, Furth EE, Vonderheide RH (2016) CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell Immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res 4:968\u2013982. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0188","journal-title":"Cancer Immunol Res"},{"key":"3309_CR163","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, Cui Y, Giles AJ et al (2014) Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 6:237ra67-237ra67. https:\/\/doi.org\/10.1126\/scitranslmed.3007974","journal-title":"Sci Transl Med"},{"key":"3309_CR164","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","volume":"31","author":"Q Liu","year":"2016","unstructured":"Liu Q, Li A, Tian Y et al (2016) The CXCL8-CXCR1\/2 pathways in cancer. Cytokine Growth Factor Rev 31:61\u201371. https:\/\/doi.org\/10.1016\/j.cytogfr.2016.08.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"3309_CR165","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1741-7015-9-48","volume":"9","author":"E Kassi","year":"2011","unstructured":"Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48. https:\/\/doi.org\/10.1186\/1741-7015-9-48","journal-title":"BMC Med"},{"key":"3309_CR166","doi-asserted-by":"publisher","first-page":"e802078","DOI":"10.1155\/2010\/802078","volume":"2010","author":"CR Balistreri","year":"2010","unstructured":"Balistreri CR, Caruso C, Candore G (2010) The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010:e802078. https:\/\/doi.org\/10.1155\/2010\/802078","journal-title":"Mediators Inflamm"},{"key":"3309_CR167","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00592-017-1039-1","volume":"54","author":"FA Cimini","year":"2017","unstructured":"Cimini FA, Barchetta I, Porzia A et al (2017) Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetol 54:961\u2013967. https:\/\/doi.org\/10.1007\/s00592-017-1039-1","journal-title":"Acta Diabetol"},{"key":"3309_CR168","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/JOE-14-0126","volume":"222","author":"CS Nunemaker","year":"2014","unstructured":"Nunemaker CS, Chung HG, Verrilli GM et al (2014) Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function. J Endocrinol 222:267\u2013276. https:\/\/doi.org\/10.1530\/JOE-14-0126","journal-title":"J Endocrinol"},{"key":"3309_CR169","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cmet.2009.03.002","volume":"9","author":"C Chavey","year":"2009","unstructured":"Chavey C, Lazennec G, Lagarrigue S et al (2009) CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 9:339\u2013349. https:\/\/doi.org\/10.1016\/j.cmet.2009.03.002","journal-title":"Cell Metab"},{"key":"3309_CR170","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P (2021) The changing landscape of atherosclerosis. Nature 592:524\u2013533. https:\/\/doi.org\/10.1038\/s41586-021-03392-8","journal-title":"Nature"},{"key":"3309_CR171","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1161\/ATVBAHA.107.161174","volume":"28","author":"A Zernecke","year":"2008","unstructured":"Zernecke A, Shagdarsuren E, Weber C (2008) Chemokines in atherosclerosis. Arterioscler Thromb Vasc Biol 28:1897\u20131908. https:\/\/doi.org\/10.1161\/ATVBAHA.107.161174","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3309_CR172","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","volume":"10","author":"RC Russo","year":"2014","unstructured":"Russo RC, Garcia CC, Teixeira MM, Amaral FA (2014) The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol 10:593\u2013619. https:\/\/doi.org\/10.1586\/1744666X.2014.894886","journal-title":"Expert Rev Clin Immunol"},{"key":"3309_CR173","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.110.961714","volume":"122","author":"M Drechsler","year":"2010","unstructured":"Drechsler M, Megens RTA, van Zandvoort M et al (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122:1837\u20131845. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.961714","journal-title":"Circulation"},{"key":"3309_CR174","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1172\/JCI1195","volume":"101","author":"WA Boisvert","year":"1998","unstructured":"Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA (1998) A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101:353\u2013363. https:\/\/doi.org\/10.1172\/JCI1195","journal-title":"J Clin Invest"},{"key":"3309_CR175","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/iub.1107","volume":"65","author":"Y Qin","year":"2013","unstructured":"Qin Y, Fan F, Zhao Y et al (2013) Recombinant human CXCL8(3\u201372)K11R\/G31P regulates smooth muscle cell proliferation and migration through blockage of interleukin-8 receptor. IUBMB Life 65:67\u201375. https:\/\/doi.org\/10.1002\/iub.1107","journal-title":"IUBMB Life"},{"key":"3309_CR176","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2012.01.013","volume":"143","author":"T N\u00e9meth","year":"2012","unstructured":"N\u00e9meth T, M\u00f3csai A (2012) The role of neutrophils in autoimmune diseases. Immunol Lett 143:9\u201319. https:\/\/doi.org\/10.1016\/j.imlet.2012.01.013","journal-title":"Immunol Lett"},{"key":"3309_CR177","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/dmrr.1257","volume":"27","author":"K Takahashi","year":"2011","unstructured":"Takahashi K, Ohara M, Sasai T et al (2011) Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity. Diabetes Metab Res Rev 27:830\u2013833. https:\/\/doi.org\/10.1002\/dmrr.1257","journal-title":"Diabetes Metab Res Rev"},{"key":"3309_CR178","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"MA Atkinson","year":"2014","unstructured":"Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet Lond Engl 383:69\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(13)60591-7","journal-title":"Lancet Lond Engl"},{"key":"3309_CR179","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11892-015-0638-x","volume":"15","author":"A Citro","year":"2015","unstructured":"Citro A, Cantarelli E, Piemonti L (2015) The CXCR1\/2 pathway: involvement in diabetes pathophysiology and potential target for T1D interventions. Curr Diab Rep 15:68. https:\/\/doi.org\/10.1007\/s11892-015-0638-x","journal-title":"Curr Diab Rep"},{"key":"3309_CR180","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.15252\/emmm.201404144","volume":"6","author":"J Diana","year":"2014","unstructured":"Diana J, Lehuen A (2014) Macrophages and \u03b2-cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes. EMBO Mol Med 6:1090\u20131104. https:\/\/doi.org\/10.15252\/emmm.201404144","journal-title":"EMBO Mol Med"},{"key":"3309_CR181","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.intimp.2013.06.034","volume":"17","author":"K Futosi","year":"2013","unstructured":"Futosi K, Fodor S, M\u00f3csai A (2013) Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int Immunopharmacol 17:638\u2013650. https:\/\/doi.org\/10.1016\/j.intimp.2013.06.034","journal-title":"Int Immunopharmacol"},{"key":"3309_CR182","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678\u2013689. https:\/\/doi.org\/10.1038\/nri2156","journal-title":"Nat Rev Immunol"},{"key":"3309_CR183","unstructured":"Sitaru S (2021) CXCR1\/2 inhibition in neutrophil recruitment. Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen"},{"key":"3309_CR184","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1189\/jlb.1003495","volume":"76","author":"SL Traves","year":"2004","unstructured":"Traves SL, Smith SJ, Barnes PJ, Donnelly LE (2004) Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 76:441\u2013450. https:\/\/doi.org\/10.1189\/jlb.1003495","journal-title":"J Leukoc Biol"},{"key":"3309_CR185","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bjp.2008.270","volume":"155","author":"A Zarbock","year":"2008","unstructured":"Zarbock A, Allegretti M, Ley K (2008) Therapeutic inhibition of CXCR2 by reparixin attenuates acute lung injury in mice. Br J Pharmacol 155:357\u2013364. https:\/\/doi.org\/10.1038\/bjp.2008.270","journal-title":"Br J Pharmacol"},{"key":"3309_CR186","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1365-2222.2011.03921.x","volume":"42","author":"R Virtala","year":"2012","unstructured":"Virtala R, Ekman A-K, Jansson L et al (2012) Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy 42:590\u2013596. https:\/\/doi.org\/10.1111\/j.1365-2222.2011.03921.x","journal-title":"Clin Exp Allergy"},{"key":"3309_CR187","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.4049\/jimmunol.1300194","volume":"192","author":"DP Dyer","year":"2014","unstructured":"Dyer DP, Thomson JM, Hermant A et al (2014) TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J Immunol 192:2177\u20132185. https:\/\/doi.org\/10.4049\/jimmunol.1300194","journal-title":"J Immunol"},{"key":"3309_CR188","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.4049\/jimmunol.171.7.3775","volume":"171","author":"TL Ness","year":"2003","unstructured":"Ness TL, Hogaboam CM, Strieter RM, Kunkel SL (2003) Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 171:3775\u20133784. https:\/\/doi.org\/10.4049\/jimmunol.171.7.3775","journal-title":"J Immunol"},{"key":"3309_CR189","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neulet.2015.08.041","volume":"606","author":"BJ Connell","year":"2015","unstructured":"Connell BJ, Gordon JR, Saleh TM (2015) ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke. Neurosci Lett 606:117\u2013122. https:\/\/doi.org\/10.1016\/j.neulet.2015.08.041","journal-title":"Neurosci Lett"},{"key":"3309_CR190","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jss.2009.04.047","volume":"162","author":"X Zhao","year":"2010","unstructured":"Zhao X, Town JR, Yang A et al (2010) A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury. J Surg Res 162:264\u2013273. https:\/\/doi.org\/10.1016\/j.jss.2009.04.047","journal-title":"J Surg Res"},{"key":"3309_CR191","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pupt.2015.02.002","volume":"31","author":"D Schneberger","year":"2015","unstructured":"Schneberger D, Gordon JR, DeVasure JM et al (2015) CXCR1\/CXCR2 antagonist CXCL8(3\u201374)K11R\/G31P blocks lung inflammation in swine barn dust-instilled mice. Pulm Pharmacol Ther 31:55\u201362. https:\/\/doi.org\/10.1016\/j.pupt.2015.02.002","journal-title":"Pulm Pharmacol Ther"},{"key":"3309_CR192","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.bbrc.2009.12.025","volume":"391","author":"S-H Min","year":"2010","unstructured":"Min S-H, Wang Y, Gonsiorek W et al (2010) Pharmacological targeting reveals distinct roles for CXCR2\/CXCR1 and CCR2 in a mouse model of arthritis. Biochem Biophys Res Commun 391:1080\u20131086. https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.025","journal-title":"Biochem Biophys Res Commun"},{"key":"3309_CR193","doi-asserted-by":"publisher","first-page":"L322","DOI":"10.1152\/ajplung.00039.2005","volume":"289","author":"TH Thatcher","year":"2005","unstructured":"Thatcher TH, McHugh NA, Egan RW et al (2005) The role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 289:L322\u2013L328. https:\/\/doi.org\/10.1152\/ajplung.00039.2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3309_CR194","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.12488","volume":"180","author":"P Opfermann","year":"2015","unstructured":"Opfermann P, Derhaschnig U, Felli A et al (2015) A pilot study on reparixin, a CXCR1\/2 antagonist, to assess safety and efficacy in attenuating ischaemia\u2013reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery. Clin Exp Immunol 180:131\u2013142. https:\/\/doi.org\/10.1111\/cei.12488","journal-title":"Clin Exp Immunol"},{"key":"3309_CR195","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1378\/chest.126.3.926","volume":"126","author":"DA Mahler","year":"2004","unstructured":"Mahler DA, Huang S, Tabrizi M, Bell GM (2004) Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126:926\u2013934. https:\/\/doi.org\/10.1378\/chest.126.3.926","journal-title":"Chest"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03309-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:33:27Z","timestamp":1744216407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":195,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03309-5","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS received support by a project grant from Domp\u00e8 Farmaceutici S.p.A. RB is a preclinical pharmacology consultant of Domp\u00e9 Farmaceutici S.p.a.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}